Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Atageldiyeva, Kuralay ^a   Fujita, Yukihiro ^a   Yanagimachi, Tsuyoshi ^a   Mizumoto, Katsutoshi ^a   Takeda, Yasutaka ^a   Honjo, Jun ^a   Takiyama, Yumi ^a   Abiko, Atsuko ^a   Makino, Yuichi ^a   Haneda, Masakazu ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOSE; GLYCOGEN; INSULIN; IPRAGLIFLOZIN; TRANSCRIPTION FACTOR FKHR; FATTY ACID SYNTHASE; FOXO1 PROTEIN, MOUSE; GLUCOSIDE; MESSENGER RNA; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; CREB1 GENE; DRUG MECHANISM; EPIDIDYMIS FAT; FAT MASS; FATTY ACID SYNTHESIS; FOOD INTAKE; FOXO1 GENE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOGEN ANALYSIS; GLYCOLYSIS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY PARENCHYMA; LIPID METABOLISM; LIVER LEVEL; LOW CARBOHYDRATE DIET; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; WEIGHT GAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT; C57BL MOUSE; CALORIC INTAKE; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENETICS; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; KIDNEY; LIVER; METABOLISM; OBESITY; PATHOLOGY; UPREGULATION;

ANIMALS; BODY WEIGHT; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DIABETES MELLITUS, EXPERIMENTAL; DIET, CARBOHYDRATE-RESTRICTED; ENERGY INTAKE; FATTY ACID SYNTHASES; FORKHEAD BOX PROTEIN O1; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; GLUCOSIDES; GLYCOGEN; HYPERGLYCEMIA; INSULIN RESISTANCE; KIDNEY; LIPID METABOLISM; LIVER; MALE; MICE, INBRED C57BL; OBESITY; RNA, MESSENGER; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TRIGLYCERIDES; UP-REGULATION;

EID: 84976904194     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157672     Document Type: Article

References (46)

1. Gopinath B, Flood VM, Rochtchina E, Baur LA, Louie JC, Smith W, et al. Carbohydrate nutrition and development of adiposity during adolescence. Obesity (Silver Spring). 2013; 21(9):1884-90. doi: 10. 1002/oby.20405 PMID: 23519919.
2. Heller RF, Heller RF. Hyperinsulinemic obesity and carbohydrate addiction: the missing link is the carbohydrate frequency factor. Med Hypotheses. 1994; 42(5):307-12. PMID: 7935072.
3. Ross AP, Darling JN, Parent MB. Excess intake of fat and sugar potentiates epinephrine-induced hyperglycemia in male rats. J Diabetes Complications. 2015; 29(3):329-37. doi: 10.1016/j.jdiacomp. 2014.12.017 PMID: 25716573.
4. Ross SM. Sugar-induced aging: the deleterious effects of excess dietary sugar intake. Holist Nurs Pract. 2015; 29(2):114-6. doi: 10.1097/HNP.0000000000000080 PMID: 25658934.
5. Ross SM. Cardiovascular disease mortality: the deleterious effects of excess dietary sugar intake. Holist Nurs Pract. 2015; 29(1):53-7. doi: 10.1097/HNP.0000000000000066 PMID: 25470481.
6. Maniecka-Bryla I, Szymocha M, Bryla M. Overweight and obesity as risk factors in hypertension-study of the working population. Med Lav. 2011; 102(6):523-38. PMID: 22332488.
7. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Med Clin North Am. 2011; 95(5):919-37. doi: 10.1016/j.mcna.2011.06.005 PMID: 21855700.
8. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009; 53(21):1925-32. doi: 10.1016/j.jacc.2008.12.068 PMID: 19460605.
9. Hu T, Yao L, Reynolds K, Whelton PK, Niu T, Li S, et al. The Effects of a Low-Carbohydrate Diet vs. a Low-Fat Diet on Novel Cardiovascular Risk Factors: A Randomized Controlled Trial. Nutrients. 2015; 7 (9):7978-94. doi: 10.3390/nu7095377 PMID: 26393645; PubMed Central PMCID: PMCPMC4586572.
10. Caminhotto Rde O, Fonseca FL, Castro NC, Arantes JP, Sertie RA. Atkins diet program rapidly decreases atherogenic index of plasma in trained adapted overweight men. Arch Endocrinol Metab. 2015; 59(6):568-71. doi: 10.1590/2359-3997000000106 PMID: 26421667.
11. Al-Khalifa A, Mathew TC, Al-Zaid NS, Mathew E, Dashti HM. Therapeutic role of low-carbohydrate ketogenic diet in diabetes. Nutrition. 2009; 25(11-12):1177-85. doi: 10.1016/j.nut.2009.04.004 PMID: 19818281.
12. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012; 7(2):e30555. doi: 10.1371/journal.pone.0030555 PMID: 22355316; PubMed Central PMCID: PMCPMC3280264.
13. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014; 16(2):159-69. doi: 10.1111/dom.12189 PMID: 23906445.
14. Ikeda S, Takano Y, Cynshi O, Tanaka R, Christ AD, Boerlin V, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015; 17(10):984-93. doi: 10.1111/dom.12538 PMID: 26179482.
15. Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, Sako A, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis. J Clin Med Res. 2016; 8(3):237-43. doi: 10.14740/jocmr2467w PMID: 26858798; PubMed Central PMCID: PMCPMC4737036.
16. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011; 32(4):515-31. doi: 10.1210/er.2010-0029 PMID: 21606218.
17. Balakumar P, Sundram K, Dhanaraj SA. Dapagliflozin: glucuretic action and beyond. Pharmacol Res. 2014; 82:34-9. doi: 10.1016/j.phrs.2014.03.008 PMID: 24705156.
18. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013; 715(1-3):246-55. doi: 10.1016/j. ejphar.2013.05.014 PMID: 23707905.
19. Horobin RW, Murgatroyd LB. The staining of glycogen with Best's Carmine and similar hydrogen bonding dyes. A mechanistic study. Histochem J. 1971; 3(1):1-9. PMID: 4106594.
20. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012; 20(8):1645-52. doi: 10.1038/oby.2012.59 PMID: 22402735.
21. Michel MC, Mayoux E, Vallon V. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn Schmiedebergs Arch Pharmacol. 2015; 388 (8):801-16. doi: 10.1007/s00210-015-1134-1 PMID: 26108304.
22. O'Malley D, Reimann F, Simpson AK, Gribble FM. Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. Diabetes. 2006; 55(12):3381-6. doi: 10.2337/db06-0531 PMID: 17130483; PubMed Central PMCID: PMCPMC1948974.
23. Yu AS, Hirayama BA, Timbol G, Liu J, Basarah E, Kepe V, et al. Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol. 2010; 299(6):C1277-84. doi: 10.1152/ajpcell.00296.2010 PMID: 20826762; PubMed Central PMCID: PMCPMC3006325.
24. Yu AS, Hirayama BA, Timbol G, Liu J, Diez-Sampedro A, Kepe V, et al. Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol. 2013; 304(3):C240-7. doi: 10.1152/ajpcell.00317.2012 PMID: 23151803; PubMed Central PMCID: PMCPMC3566441.
25. Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012; 341(3):692-701. doi: 10.1124/jpet.112.191593 PMID: 22410641.
26. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124(2):499-508. doi: 10. 1172/JCI72227 PMID: 24463454; PubMed Central PMCID: PMCPMC3904627.
27. Obata A, Kubota N, Kubota T, Iwamoto M, Sato H, Sakurai Y, et al. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology. 2015:en20151588. doi: 10.1210/en.2015-1588 PMID: 26713783.
28. Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016; 65(2):114-23. doi: 10.1016/j.metabol.2015.10.010 PMID: 26773934.
29. Handa K, Inukai K, Onuma H, Kudo A, Nakagawa F, Tsugawa K, et al. Long-term low carbohydrate diet leads to deleterious metabolic manifestations in diabetic mice. PLoS One. 2014; 9(8):e104948. doi: 10. 1371/journal.pone.0104948 PMID: 25170869; PubMed Central PMCID: PMCPMC4149431.
30. Nomura F, Ohnishi K, Suzuki T, Tanaka H, Tsunoda T, Tanabe Y, et al. Fatty liver in rats induced by excessive intake of a nutritionally adequate liquid diet. Int J Obes. 1987; 11(6):603-8. PMID: 3440681.
31. Tsunoda N, Ikemoto S, Takahashi M, Maruyama K, Watanabe H, Goto N, et al. High-monounsaturated fat diet-induced obesity and diabetes in C57BL/6J mice. Metabolism. 1998; 47(6):724-30. PMID: 9627373.
32. Green CJ, Hodson L. The influence of dietary fat on liver fat accumulation. Nutrients. 2014; 6 (11):5018-33. doi: 10.3390/nu6115018 PMID: 25389901; PubMed Central PMCID: PMCPMC4245577.
33. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One. 2016; 11(3):e0151511. doi: 10.1371/journal.pone.0151511 PMID: 26977813; PubMed Central PMCID: PMCPMC4792392.
34. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124 (2):509-14. doi: 10.1172/JCI70704 PMID: 24463448; PubMed Central PMCID: PMCPMC3904617.
35. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015; 21(5):512-7. doi: 10.1038/nm.3828 PMID: 25894829.
36. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest. 1995; 96 (5):2528-33. doi: 10.1172/JCI118314 PMID: 7593645; PubMed Central PMCID: PMCPMC185914.
37. Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014; 306(2):F194-204. doi: 10. 1152/ajprenal.00520.2013 PMID: 24226524; PubMed Central PMCID: PMCPMC3920018.
38. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003; 423(6939):550-5. doi: 10.1038/ nature01667 PMID: 12754525.
39. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001; 413(6852):179-83. doi: 10.1038/35093131 PMID: 11557984.
40. Wirthensohn G, Guder WG. Renal lipid metabolism. Miner Electrolyte Metab. 1983; 9(4-6):203-11.PMID: 6361509.
41. Wirthensohn G, Guder WG. Renal substrate metabolism. Physiol Rev. 1986; 66(2):469-97. PMID: 2938198.
42. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001; 24(2):382-91. PMID: 11213896.
43. Izumida Y, Yahagi N, Takeuchi Y, Nishi M, Shikama A, Takarada A, et al. Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to facilitate fat utilization. Nat Commun. 2013; 4:2316.
44. doi: 10.1038/ncomms3316 PMID: 23939267; PubMed Central PMCID: PMCPMC3753545.
45. Dombrowski F, Klotz L, Bannasch P, Evert M. Renal carcinogenesis in models of diabetes in rats: metabolic changes are closely related to neoplastic development. Diabetologia. 2007; 50(12):2580-90. doi: 10.1007/s00125-007-0838-2 PMID: 17952403.
46. Ritchie S, Waugh D. The pathology of Armanni-Ebstein diabetic nephropathy. Am J Pathol. 1957; 33 (6):1035-57. PMID: 13478656; PubMed Central PMCID: PMCPMC1934668.